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Data are presented on pharmacodynamic (PD) method validation and preliminary clinical qualification of three PD biomarker assays.
M65 Elisa, which quantitates different forms of circulating cytokeratin 18 (CK18) as putative surrogate markers of both apoptotic and
nonapoptotic tumour cell death, was shown to be highly reproducible: calibration curve linearity r
2¼0.996, mean accuracy 491%
and mean precision o3%, n¼27. Employing recombinant (r) CK18 and caspase cleaved CK18 (CK18 Asp
396 neo-epitope) as
external standards, kit to kit reproducibly was o6% (n¼19). rCK18 was stable in plasma for 4 months at  201C and  801C, for 4
weeks at 41C and had a half-life of 2.3 days at 371C. Cytokeratin 18 Asp
396 NE, the M30 Apoptosense Elisa assay antigen, was stable
in plasma for 6 months at  201C and  801C, for 3 months at 41C, while its half-life at 371C was 3.8 days. Within-day variations in
endogenous plasma concentrations of the M30 and M65 antigens were assessed in two predose blood samples collected from a
cohort of 15 ovarian cancer patients receiving carboplatin chemotherapy and were shown to be no greater than the variability
associated with methods themselves. Between-day fluctuations in circulating levels of the M30 and M65 antigens and in XIAP mRNA
levels measured in peripheral blood mononuclear cells by quantitative (q) RT–PCR were evaluated in two predose blood samples
collected with a 5- to 7-day gap from 23 patients with advanced cancer enrolled in a phase I trial. The mean variation between the
two pretreatment values ranged from 13 to 14 to 25%, respectively, for M65, M30 and qRT–PCR. These data suggest that the M30
and M65 Elisa’s and qRT–PCR as PD biomarker assays have favourable performance characteristics for further investigation in clinical
trials of anticancer agents which induce tumour apoptosis/necrosis or knockdown of the anti-apoptotic protein XIAP.
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AEG35156 is a second generation, mixed backbone, 19-mer
antisense oligonucleotide targeting the inhibitor of apoptosis
protein XIAP and is currently undergoing Phase I clinical
evaluation at two centres in the UK (Ranson et al, 2005).
Considerable evidence has now accrued through application of a
broad range of technologies to a wide spectrum of in vitro and in
vivo model systems to substantiate XIAP as a valid molecular
target in cancer therapeutics (Lacasse et al, 2005; Wright and
Duckett, 2005; Schimmer et al, 2006). A unique feature of the
ongoing AEG35156 clinical studies is that a number of pharma-
codynamic (PD) biomarker assays have been incorporated into the
trial design in order to seek confirmatory evidence of target
knockdown and concomitant downstream effects. In addition
many other anticancer agents act by inducing apoptosis or
necrosis and reliable biomarkers of drug effect are required (Bast
et al, 2005; Ludwig and Weinstein, 2005).
In a recent publication, analytical method validation of three
different PD biomarker assays was reported: quantitative RT–PCR
(qRT–PCR) for XIAP mRNA expression, Western blot analysis for
XIAP protein expression, and a novel plasma Elisa assay (M30
Apoptosense) as a surrogate marker of tumour cell apoptosis
(Cummings et al, 2005). During that study method validation was
conducted in accordance with available internationally recognised
bioanalytical guidelines established by the pharmaceutical indus-
try, but primarily utilised in drug and safety monitoring (Shah
et al, 2000; Miller et al, 2001). There is a growing acknowledgement
that these guidelines are not sufficiently flexible to accommodate
the many different categories of PD assays that are employed
during anticancer drug development of molecularly targeted
agents (Lee et al, 2005). It is now also evident that qualification
of a biomarker is a multistage process requiring a concerted team
effort often paralleling the drug development cycle (Colburn, 2003;
Benowitz, 2004; Ransohoff, 2004; Ludwig and Weinstein, 2005).
For PD biomarker assays at least four distinct categories
were identified each requiring evaluation of a different set of Received 30 March 2006; revised 12 May 2006; accepted 17 May 2006
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sperformance criteria: definitive quantitative (e.g. mass spectro-
metry), relative quantitative (e.g. Western blot analysis),
quasiquantitative (e.g. qRT–PCR) and qualitative (e.g.
immunohistochemistry) (Lee et al, 2005).
A vital component in PD biomarker validation is the establish-
ment of its pretreatment range and inherent biovariability, in
order to assess the likelihood that the technology of choice and
trial design have the statistical and technological resolving power
to discriminate between normal background biologic variation and
a drug-induced effect (Lee et al, 2005). In the present paper,
analytical validation of a fourth PD assay, the M65 Elisa (Kramer
et al, 2004), is described, along with long term stability studies on
the antigens for this assay as well as for M30 Apoptosense (Biven
et al, 2003; Kramer et al, 2004). In addition, an evaluation
of predose biomarker variability in cancer patients is presented for
the M30 and M65 cell death Elisa’s and a qRT–PCR method for
XIAP mRNA.
MATERIALS AND METHODS
Reagents
Custom synthesised PCR primers for XIAP, the XIAP-specific
Taqman probe and all other core reagents for qRT–PCR were as
previously reported in full (Cummings et al, 2005). Staurosporine
was from the Sigma Chemical Company (Poole, England, UK).
Recombinant human Cytokeratin 18 (rCK18, catalogue number
RDI-PRO62217) was from Research Diagnostics Inc. (Flanders, NJ,
USA) and upon arrival was separated into 1mg aliquots and stored
at  801C before use. Caspase cleaved CK18 Asp
396 neo-epitope
(CK18 Asp
396 NE, see Figure 1) was produced by incubation of
MDA-MB-231/X-G4 cells (XIAP knockdown) (McManus et al,
2004) with 1mM staurosporine for 48h, under conditions resulting
in maximum induction of apoptosis and optimal release of the
21kDa peptide fragment into tissue culture media (Bantel et al,
2004; Cummings et al, 2005). The conditioned media was
centrifuged at 1000g for 20min to remove cellular debris and
the supernatant was adjusted with fresh media to yield a stock
concentration of M30 antigen of 10000Ul
 1, where 1U is
equivalent to 1.24pmol of peptide (Ueno et al, 2003). The stock
solution of M30 antigen was aliquoted and stored at  801C before
use. The M30 Apoptosense and M65 Elisa kits were both obtained
from PEVIVA AB (Bromma, Sweden). All other chemicals,
reagents and buffers were of the highest grade available
commercially and water was purified and deionised in a Millipore
Elix 3 system (Millipore, Watford, England, UK).
Preparation of quality control samples of volunteer human
plasma containing either M30 or M65 antigens for stability
studies
Blood was collected from a group of healthy volunteers with
informed consent in the registered phlebotomy centre of the
Paterson Institute for Cancer Research, Manchester, UK. Plasma
was immediately separated by centrifugation at 1000g for 10min
and the supernatants pooled. To one-half of the pooled plasma was
added freshly thawed rCK18 to achieve a final concentration of
M65 antigen of circa 1500Ul
 1 and to the other half of the pool
was added CK18 Asp
396 NE to achieve a final concentration of M30
antigen of circa 800Ul
 1. Each lot of pooled plasma was
thoroughly mixed and centrifuged, before aliquoting into approxi-
mately 200 individual 1.5ml polypropylene tubes to be used as QC
samples in long-term stability studies and in method validation of
the M65 assay.
Collection of predose blood samples from cancer patients
for M65 and M30 Elisa analysis
Samples were utilised from two separate trials following informed
consent. In the first, two predose samples were obtained from
cancer patients with a 5- to 7-day gap between collections as part
of a phase I trial of the XIAP inhibitor AEG35156. In this case, 5ml
of venous blood was drawn into a vacutainer tube containing
heparin anticoagulant. Within 30min of collection bloods were
centrifuged at 1000g for 10min to obtain plasma and the plasma
transferred to 3ml polypropylene cyrotubes. Tubes were then
frozen at  201C within 30min and transferred to  801C within
3h. In the second study, two predose samples were obtained from
cancer patients within the same day. The aim of this study was to
establish the baseline values and variability in endogenous plasma
levels of full-length CK18 and CK18 Asp
396 NE in patients with
ovarian cancer before and during treatment with platinum based
chemotherapy. The sample handling protocol was essentially the
same as in the AEG35156 phase I trial. All samples from both trials
were analysed within 4 months of collection.
The M65 Elisa assay
The M65 Elisa assay is a commercially available kit based on a 96-
well plate format, it consists of a seven-point calibration curve
(125–2000Ul
 1 of antigen) and certified low and high quality
controls (QC, circa 200 and 1000Ul
 1), and was operated
according to the manufacturer’s instructions. In brief, 25mlo f
sample (standard, blank, QC, or patient plasma sample) was added
to each well, which was coated with a mouse monoclonal ‘catcher’
antibody that binds to an epitope on CK18 (M6 antibody, see
Figure 1). Simultaneously, 75ml of HRP-conjugated monoclonal
antibody (M5) solution was added to act as the detection antibody
(Kramer et al, 2004). Samples were then incubated for 2h at room
temperature with constant shaking, after which excess unbound
conjugate was removed by addition of the wash solution, times
five. Colour development was achieved by incubation with 200ml
of 3,30,5,50-tetramethyl-benzidine solution for 20min in the dark.
The reaction was stopped with 50ml of 1.0 M sulphuric acid and
absorbance was finally measured in a microplate reader at 450nm.
By plotting a standard curve of known concentrations of M65
antigen standards vs absorbance, the amount of antigen in the QCs
and unknown samples was calculated by interpolation. The M30
Apoptosense assay was performed as previously published
(Cummings et al, 2005).
M30 Apoptosense
1 429
Cytokeratin 18
Caspase 6 3/7/9
1 238 429 396
396
M65 ELISA
M5
M5 M30
M6
Figure 1 Schematic representation of the CK18 epitope map targeted
by the antibodies used in the M30 Apoptosense and M65 sandwich Elisa
assays. In the case of M65 Elisa the M6 antibody acts as the catcher and M5
as detection antibody. For the M30 Apoptosense assay M5 was the catcher
and HRP-conjugated M30 the detection antibody.
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determination by qRT-PCR
Venous blood samples (approximately 2.5ml) for XIAP mRNA
analysis were collected from a cohort of cancer patients entered
into the AEG35156 Phase I trial. Two predose samples were
obtained from the patients with normally a 5- to 7-day gap between
collections as part of the full PD protocol. Venous blood samples
were collected into 2.5ml PAXgene Blood RNA extraction tubes
(PAXgene Blood RNA kit, PreAnalytiX/Qiagen, Catalogue Number,
762132, Valencia, CA, USA). The PAXgene tubes were inverted 8–
10 times and cells lysed at room temperature for 2–24h before
being frozen at  201C after which they were transferred to  801C
storage.
Frozen PAXgene tubes were allowed to thaw for 4h before
centrifugation at 2490g for 20min in a swing out rotor and the
supernatants discarded (IEC Centra GP8R bench top centrifuge).
Pellets were resuspended in RNase-free water (5ml), further
centrifuged as above and finally resuspended in 360ml buffer BR1
(PAXgene Blood RNA kit, PreAnalytiX/Qiagen) by vortexing.
Tubes were then incubated for 10min at 551C in a 280g shaker-
incubator with 40ml Proteinase K and 300ml buffer BR2. At the end
of the incubation 350ml of 100% ethanol was added and the total
sample was then applied on to the PAXgene extraction column
together with 350ml of buffer BR3 and centrifuged at 8000g for
1min in a minifuge discarding the flow through waste. Next the
extraction columns were incubated with DNase I (10ml DNase I
stock solution to 70ml Buffer RDD) for 15min at room
temperature. Extraction columns were then washed with 350ml
buffer BR3 as above, followed by two washes and spins with 500ml
of buffer BR4, the later performed at maximum speed (16000g) for
3min to dry the PAXgene column membrane. The columns were
finally eluted with 40ml of buffer BR5 and the eluent collected in a
0.5ml tube after a spin at 8000g for 1min. The final eluent was
incubated for 5min at 651C in a heating block, then chilled on ice
and the harvested RNA was stored at  801C. qRT–PCR was then
performed essentially as described in detail (Fong et al, 2000;
McKinnon et al, 2002; Hu et al, 2003; Cummings et al, 2005). All
the RT–PCR steps were carried out in an ABI Prism 7700 Sequence
Detector, and quantitation was by the cycle threshold (CT)
method.
RESULTS AND DISCUSSION
Method validation of the M65 Elisa assay
We have previously shown that the M30 assay yields a sigmoidal
calibration curve of the type often associated with sandwich Elisa
assays (Miller et al, 2001; Cummings et al, 2005). Here, we show
that the M65 assay produces a linear calibration curve over the
concentration range of 125–2000U/l
 1, with a mean regression
correlation coefficient (r
2) value of 0.99670.003 (n¼27). The
linear response is believed to be due to the high affinity constants
(10
 13 M) of the two mouse monoclonal antibodies utilised, M6 and
M5 (Kramer et al, 2004), for their respective CK18 epitopes and the
subsequent faster reaction kinetics (Peter Bjo ¨rklund, PEVIVA,
personal communication). Thus, the M65 Elisa assay only requires
a 2h incubation time period as compared to a 4h incubation for
M30 Apoptosense.
The M65 Elisa also proved to be highly reproducible with
precision and accuracy (P and A) based on values obtained using
the in kit QCs (200 and 1000Ul
 1) (Table 1). Furthermore,
precision and kit to kit reproducibility data were generated by
use of independent external standard QCs consisting of both
rCK18 and CK18 Asp
396 NE added to human plasma (see Table 1).
These studies were conducted over an 18-month period and
were generated after running a total of 27 assays using 19 different
kits, comprising three different production batches. Each experi-
ment consisted of a seven point calibration curve run in duplicate,
including a blank, while replicates numbers of each QC run
per experiment ranged from n¼3–8. Mean P and A achieved with
the in kit QCs normally varied by o5% with the exception of
accuracy for the low QC which varied by 8.3% (yielding a mean of
91.7% of that of its nominal value). This bias was introduced
exclusively by kits from the earliest production batch, and
appeared to be eliminated in the subsequent two production
batches. Utilising the external standards, mean kit to kit variations
in the concentration of antigen determined was 5.3% with rCK18
and 4.8% with CK18 Asp
396 NE, normally well within the
manufacturer’s acceptance criteria of 10%, (http://web.peviva.se/
index.asp).
Unlike the M30 Apoptosense Elisa that relies on caspase
cleavage to reveal a neo-epitope mapped to positions 387–396 of
CK18 (Ku et al, 1997; Leers et al, 1999), the M65 Elisa utilises
the M6 antibody to capture and an HRP-conjugated M5 antibody
to detect epitopes present in a domain common to the intact
protein as well as the 21kDa caspase cleaved fragment (see
Figure 1) (Kramer et al, 2004). Although, intact CK18 is viewed
as a stable insoluble structural component of the intermediate
filaments (Fuchs and Weber, 1994), proliferating cells also
possess a substantial pool of soluble CK18, which increases upon
stress due to remodelling of cellular structure (Chou et al, 1993;
Ku et al, 1997). Recently, cancer cells undergoing necrotic
death have been shown to release intact CK18 in a manner
analogous to the release of its caspase cleaved fragment from
cells undergoing apoptosis (Kramer et al, 2004; Schutte et al,
2004). Thus, the M65 Elisa potentially detects both necrotic
and apoptotic components, although it is unclear whether or
not this assay is capable of detecting all presently known cell
death mechanisms such as autophagy and mitotic catastrophe
(Broker et al, 2005). Nevertheless, since both the M30 and M65
assays are calibrated with the same recombinant CK18 peptide
fragment (CK18 Asp
396 NE), their readouts are directly com-
parable and the ratio of the signal measured by each enables
differentiation between cell death modes (Kramer et al, 2004).
We have confirmed by use of our standard of caspase cleaved
CK18 that both assays do indeed produce very similar results,
normally within 10% of each other, whereas the M30 Apoptosense
assay exhibits, as expected, very little cross reactivity for intact
rCK18.
Table 1 Reproducibility of the M65 Elisa assay
QC standard Mean accuracy (%) Mean precision (%) Number of assays
Low In kit QC (200Ul
 1) 91.7 (range 73.1–109.7) 1.0 (range 0.8–16.7) 27
High In Kit QC (1000Ul
 1) 102.5 (range 95.9–115.4) 2.9 (range 0.3–9.8) 27
Mean precision (%) Kit to kit CV (%) Number of kits
rCK18 (circa 1500Ul
 1) 2.9 (range 1.3–6.6) 5.3 (range 1.5–11.6) 8
CK18 Asp
396 NE (circa 800Ul
 1) 2.0 (range 0.6–3.1) 4.8 (range 2.3–7.3) 4
Abbreviations: CK18¼cytokeratin 18; QC¼quality controls.
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Long-term stability studies were conducted in order to establish
the maximal period of time that human plasma could be stored at
different temperature without in situ analyte degradation occur-
ring. Six-month stability of both the M30 and M65 antigens in
pooled volunteer plasma was studied at 41C,  201C and  801C
(Figures 2 and 3, respectively). In addition, plasma containing both
M30 and M65 antigens were subjected to three cycles of freeze
thawing at  801C (data not shown).
The M30 antigen (CK18 Asp
396 NE, see Figure 1) was shown to
be stable over 6 months at both  201C and  801C (Figure 2),
where instability is defined as a significant reduction by Students t-
test in concentration between two consecutive time points. After 6
months incubation at  801C instability was demonstrated at the 8
month time with an 11.1% reduction in value (P¼o0.01) (data
not shown). At 41C clear fluctuations in concentration were
recorded, whereby after 4 months a small but significant reduction
in value was observed followed by a larger increase after 6 months.
A small but significant (Po0.01) reduction in concentration of
full-length rCK18 occurred after 6 months at both  201C and
 801C (10.9 and 19.9%, respectively) (Figure 3) indicating that the
stability of the M65 antigen is restricted to only 4 months at these
temperatures. Whereas at 41C stability was only evident for 4
weeks, after which time a consistent rise in concentration occurred
for up to 3 months before levels started to fall. Samples subjected
to three cycles of freeze thawing had no deleterious effect on the
concentration of both M30 and M65 antigens.
Accelerated stability was also investigated at 371C using
individual volunteer plasma samples spiked at a higher concentra-
tion of rCK18 in order to accommodate for the more rapid decline
in concentration (10000Ul
 1, Figure 4). In this case the aim was
to address the issue of whether or not the M65 and M30 antigens
are sufficiently stable in plasma at body temperatures to provide
meaningful quantitative information on the kinetics of cell death
occurring at distal sites in the body such as a tumour. Although the
early stages of apoptosis occur within minutes, the final stages of
lysosomal degradation can extend into hours, depending on cell
type and tissue (Holdenrieder and Stieber, 2004a) and a lag period
in the region 6–10h has been reported before cleaved cytokeratin
products are released from apoptotic bodies and necrotic cells
(Einarsson and Barak, 1997; Schutte et al, 2004). Nonetheless, the
stability studies conducted at 371C yielded a mean half-life of 2.3
days for rCK18 in human plasma (Figure 4), compared to 3.8 days
for CK18 Asp
396 NE (Cummings et al, 2005).
The presence of different keratins in either plasma or serum of
cancer patients has been recognised for many years and used as
tumour markers in the diagnosis of cancer (Weber et al, 1984;
Sundstrom and Stigbrand, 1994; Silen et al, 1995; Dobashi et al,
2000; Barak et al, 2004; Seregni et al, 2004). Therefore, it may be
surprising that few publications have focused on the formal
stability of these proteins as analytes in the systematic manner
reported herein. Perhaps, in the case of keratins long term stability
has always been presumed. Keratins are primarily responsible for
providing cytoskeletal rigidity, and are now even believed to
protect cells against chemical toxicity (Owens and Lane, 2003).
Indeed, good physical and chemical stability has been demon-
strated in a number of studies, especially in the case of the caspase
cleaved fragments of CK18 (Ku et al, 1997; Carr, 2000; Aho, 2004).
We have also confirmed that caspase cleaved CK18 is considerably
more stable than the intact protein.
An unexpected finding of this work was that statistically
significant increases in concentration of both intact CK18 and its
caspase cleaved fragment occurred during the stability studies. A
similar effect has also been observed in long–term stability of CK18
Asp
396 NE in tissue culture media (Cummings et al, 2005).
Investigations on keratin 8/18 breakdown and reorganisation
during apoptosis have shown that the M30 antigen is released from
apoptotic cells as large aggregates, which are believed to promote
their stability in the circulation, including avoidance of uptake and
clearance by the reticuloendothelial system (Schutte et al, 2004). It
is likely that the CK18 Asp
396 NE standard used in the present
work, which was generated by the induction of apoptosis in cancer
cells in vitro, also consists of aggregates. The possibility exits that
with time these aggregates dissociate to reveal more epitope sites
for antibody interaction thus giving the appearance of an increase
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Figure 2 Stability of caspase cleaved CK18 (Asp
396 neo-epitope, see
Figure 1) in human volunteer plasma determined by the M30 Apoptosense
assay. Each time point represents the mean value7standard deviation (s.d.)
of n¼3–8 replicates.
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Figure 3 Stability of recombinant human cytokeratin 18 in human
volunteer plasma determined by the M65 Elisa assay. Each time point
represents the mean value7s.d. of n¼3–8 replicates.
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Figure 4 Stability of recombinant human CK18 in human volunteer
plasma incubated at 371C determined by the M65 Elisa assay. Each time
point represents duplicate measurements. The mean half-life was 2.3 days.
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sin concentration. Cytokeratin 18 also has a strong propensity to
form higher complexes both with keratin and non-keratin proteins
(Liao and Omary, 1996; Hofmann and Franke, 1997; Coulombe
et al, 1998) and can be detected in the circulation as a range of
small and large polymeric protein complexes referred to as tissue
polypeptide-specific antigen (TPS) (Rydlander et al, 1996). There-
fore, as with the M30 antigen, it is conceivable that association
occurs in situ when rCK18 is added to plasma and that with time
these complexes also slowly disassociate, before the onset of
proteolytic destruction or chemical degradation. Alternatively, in
the case of intact rCK18 protein unfolding could occur with time
and that might increase the accessibility of the detection antibody
(M5) for its epitope. Possible explanations for the increase in
concentration are currently under investigation.
Within-day and between-day variability in baseline values
of M30 and M65 antigens in cancer patients
Within-day variations in the baseline levels of circulating M30 and
M65 antigens detected in a cohort of 15 ovarian cancer patients are
presented in Figure 5, while between-day variations obtained by
analysis of two predose samples collected 5–7 days apart from
patients entered into the AEG35156 trial are shown in Figure 6. In
these studies, the M65 assay was used to determine M65 antigen,
while the M30 Apoptosense assay was used to determine the M30
antigen. For within-day, the percentage differences measured
(5.0% average for M30 and 4.1% average for M65) were within, or
at least close to, the normal levels of variability associated with the
methods indicating a comparatively small contribution from the
biomarker itself. These data are in contrast to many typical plasma
PD assays which are often associated with 30% or greater
imprecision (Miller et al, 2001; Lee et al, 2005).
In the case of between-day (Figure 6), a much greater level of
variation was detected, as might be expected, which clearly
included a component due to biological variability. Nonetheless,
the mean variation was 14.1% for M30 and 12.9% for M65 and only
in one example (M30 for patient 3) did this value exceed 30%
(Miller et al, 2001; Lee et al, 2005).
Traditionally, detection of a keratin antigen in serum or plasma,
such as tissue polypeptide antigen (TPA, fragments of CK8, 18 and
19), TPS (CK18 fragments and complexes) and CYFRA 21-1
(caspase cleaved CK19), has been viewed as a marker of bulk
tumour burden (Barak et al, 2004; Seregni et al, 2004) while, some
reports have suggested that they might also predict treatment
outcome and overall survival (Einarsson and Barak, 1997; Takada
et al, 2004). However, it is now believed that the presence of M30,
M65 and TPS antigens in the circulation may be more indicative of
active processes taking place in the tumour such as apoptosis or
other forms of cell death (Einarsson and Barak, 1997; Ueno et al,
2003; Kramer et al, 2004; Schutte et al, 2004). Indeed, other keratin
markers such as TPA and CYFRA21-1, which consist of caspase
cleaved fragments, are now also being proposed to be markers of
apoptosis rather than tumour volume (Dohmoto et al, 2001;
Kramer et al, 2004). Thus, the between-day fluctuations observed
in the present study in baseline levels of M30 and M65 are more
likely to be illustrative of tumour growth dynamics reflecting the
balance between cellular proliferation and attrition due to cell
death (Evan and Vousden, 2001; Lowe et al, 2004).
The ideal circulating surrogate cancer PD biomarker assay
would be specific for tumour cells (Levenson, 2004; Lee et al,
2005). M30 and M65 Elisa’s do show a higher degree of specificity
compared to other surrogate markers of cell death such as serum
nucleosomal DNA Elisa (nDNA) (Holdenrieder and Stieber,
2004a,b), in that they are not subject to interference by bone
marrow cell death. Notwithstanding, the M30 and M65 Elisa’s
would not be capable of distinguishing between circulating CK18
forms arising from normal tissue cell death as compared to tumour
cell death. A spate of recent publications have reported that the
M30 assay will detect an increased signal in the serum of patients
with chronic hepatitis, liver toxicity due to viral infection and
critical illness due to sepsis (Bantel et al, 2004; Roth et al, 2004;
Kronenberger et al, 2005). These medical conditions, at least in an
attenuated form, may also be present in cancer patients due to
issues such as general state of health, presence of viral infections
and morbidity caused by the toxic side effects of therapy.
Nonetheless, in the present study over a 5–7 days period in a
group of 23 patients variations in the baseline levels of the M30
and M65 assays did not normally exceed 30%, whereas by contrast
in sepsis a 400% increase in circulating M30 was detected (Roth
et al, 2004), in fibrotic liver injury and chronic hepatitis a 250%
increase occurred (Kronenberger et al, 2005) and after treatment
with estamustine/vinorelbine chemotherapy a greater than 200%
increase has been reported (Kramer et al, 2004). Indeed, taking a
two-fold increase in signal over mean noise as significant (Kramer
et al, 2004), this would translate into an increase of 428% for M30
and 426% for M65 being characterised as a positive result. Clearly
the M30 and M65 have considerable spare dynamic range to record
even a modest effect on tumour cell death/apoptosis.
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Figure 6 Between-day variations in baseline, predose plasma values of
M30 and M65 antigens and XIAP mRNA measured in PBMCs by qRT–
PCR. Two separate blood samples were obtained from patients entered
into the AEG35156 phase I with a 5- to 7-day gap between collections. The
percentage difference in the two results for each patient is presented in the
graph. In these studies the M65 assay was used to determine the M65
antigen, while the M30 Apoptosense assay was used to determine the M30
antigen.
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Figure 5 Within-day variations in baseline, predose values of M30 and
M65 antigens in plasma of ovarian cancer patients before treatment with
Carboplatin. Two separate blood samples were obtained with a 1–8h gap
between collections. The percentage difference in the two results for each
patient is presented in the graph. In these studies the M65 assay was used
to determine the M65 antigen, while the M30 Apoptosense assay was used
to determine the M30 antigen.
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and variability in XIAP mRNA expression determined by
qRT–PCR
The graph of between-day variations in predose baseline levels of
XIAP mRNA in peripheral blood mononuclear cells (PBMCs) is to
found in Figure 6. Here, the mean variation was established to be
25%, ranging from 0.2 to 157%. These values are higher than for
the M30 and M65 and this was surprising, for two reasons. First,
although qRT–PCR is only considered a quasiquantitative
method, since it lacks calibration with an authentic standard, it
nevertheless generates numerical results, with a high degree of
precision, normally less than 5% and often exceeding the M30 and
M65 Elisa’s in performance (Dumur et al, 2002; Jones et al, 2003;
Cummings et al, 2005). Second, qRT–PCR of XIAP mRNA should
be subject to fewer potential variables than the M30 and M65
assays (see above). Thus, we believe that the high degree of
variability observed in Figure 6 is probably due to genuine
between-day fluctuations in XIAP mRNA expression in the two
predose PBMC samples collected from the different cancer
patients. To the best of our knowledge, no similar study has been
published addressing the issue of biomarker variability in XIAP
mRNA levels in PBMCs in cancer patients or normal volunteers.
The differences we observed may possibly be explained either by
changes in leucocyte populations expressing varying amounts of
XIAP, and/or increases in cellular XIAP levels due to cell division
or stimulation with G-CSF or GM-CSF. Both these cytokines
have been reported to induce XIAP in leucocytes or AML cells at
the protein level (Lin et al, 2002; Zhang et al, 2002; O’Neill et al,
2004).
The measurement of XIAP mRNA expression in PBMCs
represents the primary PD assay being utilised in the AEG35156
trial (Cummings et al, 2005). Current thinking suggests that a total
knockout of XIAP in tumour would not necessarily be required
rather a partial knockdown may be sufficient to lower the
apoptotic threshold to take advantage of the intrinsic proapoptotic
signalling cascades presumed to be operative in many cancers
(Kaufmann and Vaux, 2003; Reed, 2003; Wright and Duckett,
2005). Therefore, only a 50% reduction may be sufficient to
produce a therapeutic effect (Lacasse et al, 2005). Returning to the
2  signal to noise rule, in the case of the present qRT–PCR
method, a knockdown of greater than 50% would be required to be
considered a valid result, although even here one must be aware
that extreme outliers are not uncommon (Figure 6). To counteract
this problem a potential solution may be to conduct repeated and
relatively frequent determinations of XIAP mRNA levels during
therapy where a consistent trend may emerge that can then be
more confidently distinguished from background variability.
It should be noted that the number of patients employed in both
trials to evaluate variability in baseline values of M30 and M65
antigens and XIAP mRNA are based on typical phase I trial
numbers (15–23). The present studies are intended as a first stage,
and have yielded encouraging results. We are in the process of
conducting further and larger clinical studies utilising the M30 and
M65 assays as biomarkers of tumour cell death, not just from the
point of view of method validation and baseline studies, but
eventually to provide definitive proof or otherwise as to the clinical
validity and utility of M30 and M65 as surrogate PD biomarkers of
tumour cell death – biomarker qualification (Lee et al, 2005).
In summary, data are presented demonstrating that the M65
Elisa is a highly reproducible assay for the determination of CK18
and CK18 Asp
396 NE in human plasma. The stability studies have
revealed that caspase cleaved CK18 is more stable than the intact
protein and that long-term storage of samples is not recommended
for more than 4 months even at  201C and  801C. Finally, we
show in patient studies that the typical baseline variation in the
analytes of the M30 and M65 Elisa’s and a qRT–PCR method for
XIAP mRNA is comparatively small at 14, 13 and 25%,
respectively.
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